Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination

Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at high risk of morbidity and mortality. Sacubitril valsartan (previously known as LCZ696) is a new oral agent approved for the treatment of symptomatic chronic heart failure in adults with reduced ejection fra...

Descripción completa

Detalles Bibliográficos
Autor principal: Kaplinsky, Edgardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Science Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5253408/
https://www.ncbi.nlm.nih.gov/pubmed/28133468
http://dx.doi.org/10.11909/j.issn.1671-5411.2016.11.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5253408/
https://www.ncbi.nlm.nih.gov/pubmed/28133468
http://dx.doi.org/10.11909/j.issn.1671-5411.2016.11.006

Ejemplares similares